|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 11. Treatment with the RARß agonist BMS453 decreases RA signalling in the
frontonasal process and tail. External views (A-C,G-I) and frontal
histological sections (D-F) of embryos carrying the Rare-hsp68-lacZ
transgene in a wild-type genetic background. Transgenic embryos were cultured
for 24 hours (G-I) or 30 hours (A-F) in the presence of vehicle (A,D,G),
BMS453 (B,E,H) and the panRAR-selective agonist TTNPB (C,F,I). aE, anterior
part of the pharyngeal endoderm; F, frontonasal process; FO, forebrain; D,
mesonephric duct; G, foregut; H, heart; M, mesenchyme of the frontonasal
process; OV, optic vesicle; SC, spinal cord; T, tail. Scale bar in F: 400
µm for D-F.
|
